These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7937818)

  • 1. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.
    Sabzevari H; Gillies SD; Mueller BM; Pancook JD; Reisfeld RA
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9626-30. PubMed ID: 7937818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
    Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2.
    Pancook JD; Becker JC; Gillies SD; Reisfeld RA
    Cancer Immunol Immunother; 1996 Feb; 42(2):88-92. PubMed ID: 8620525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.
    Lode HN; Xiang R; Dreier T; Varki NM; Gillies SD; Reisfeld RA
    Blood; 1998 Mar; 91(5):1706-15. PubMed ID: 9473237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant antibody fusion proteins for cancer immunotherapy.
    Reisfeld RA; Gillies SD
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():27-53. PubMed ID: 8815009
    [No Abstract]   [Full Text] [Related]  

  • 9. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
    Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model.
    Yamamoto T; Arakawa F; Nakamura K; Senba T; Tomita Y; Ikeda S; Kuroki M
    Cancer Immunol Immunother; 1999 Jul; 48(4):165-71. PubMed ID: 10431685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
    Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
    Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
    Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
    Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.
    Lode HN; Xiang R; Duncan SR; Theofilopoulos AN; Gillies SD; Reisfeld RA
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8591-6. PubMed ID: 10411920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
    Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
    Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
    Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
    J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
    Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
    Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
    Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.
    Barker E; Mueller BM; Handgretinger R; Herter M; Yu AL; Reisfeld RA
    Cancer Res; 1991 Jan; 51(1):144-9. PubMed ID: 1988079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.